TY - JOUR
T1 - Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice
AU - Chalaris, Athena
AU - Adam, Nina
AU - Sina, Christian
AU - Rosenstiel, Philip
AU - Lehmann-Koch, Judith
AU - Schirmacher, Peter
AU - Hartmann, Dieter
AU - Cichy, Joanna
AU - Gavrilova, Olga
AU - Schreiber, Stefan
AU - Jostock, Thomas
AU - Matthews, Vance
AU - Häsler, Robert
AU - Becker, Christoph
AU - Neurath, Markus F.
AU - Reiß, Karina
AU - Saftig, Paul
AU - Scheller, Jürgen
AU - Rose-John, Stefan
PY - 2010/8/2
Y1 - 2010/8/2
N2 - The protease a disintegrin and metalloprotease (ADAM) 17 cleaves tumor necrosis factor (TNF), L-selectin, and epidermal growth factor receptor (EGF-R) ligands from the plasma membrane. ADAM17 is expressed in most tissues and is up-regulated during inflammation and cancer. ADAM17-deficient mice are not viable. Conditional ADAM17 knockout models demonstrated proinflammatory activities of ADAM17 in septic shock via shedding of TNF. We used a novel gene targeting strategy to generate mice with dramatically reduced ADAM17 levels in all tissues. The resulting mice called ADAM17ex/ex were viable, showed compromised shedding of ADAM17 substrates from the cell surface, and developed eye, heart, and skin defects as a consequence of impaired EGF-R signaling caused by failure of shedding of EGF-R ligands. Unexpectedly, although the intestine of unchallenged homozygous ADAM17ex/ex mice was normal, ADAM17ex/ex mice showed substantially increased susceptibility to inflammation in dextran sulfate sodium colitis. This was a result of impaired shedding of EGF-R ligands resulting in failure to phosphorylate STAT3 via the EGF-R and, consequently, in defective regeneration of epithelial cells and breakdown of the intestinal barrier. Besides regulating the systemic availability of the proinflammatory cytokine TNF, our results demonstrate that ADAM17 is needed for vital regenerative activities during the immune response. Thus, our mouse model will help investigate ADAM17 as a potential drug target.
AB - The protease a disintegrin and metalloprotease (ADAM) 17 cleaves tumor necrosis factor (TNF), L-selectin, and epidermal growth factor receptor (EGF-R) ligands from the plasma membrane. ADAM17 is expressed in most tissues and is up-regulated during inflammation and cancer. ADAM17-deficient mice are not viable. Conditional ADAM17 knockout models demonstrated proinflammatory activities of ADAM17 in septic shock via shedding of TNF. We used a novel gene targeting strategy to generate mice with dramatically reduced ADAM17 levels in all tissues. The resulting mice called ADAM17ex/ex were viable, showed compromised shedding of ADAM17 substrates from the cell surface, and developed eye, heart, and skin defects as a consequence of impaired EGF-R signaling caused by failure of shedding of EGF-R ligands. Unexpectedly, although the intestine of unchallenged homozygous ADAM17ex/ex mice was normal, ADAM17ex/ex mice showed substantially increased susceptibility to inflammation in dextran sulfate sodium colitis. This was a result of impaired shedding of EGF-R ligands resulting in failure to phosphorylate STAT3 via the EGF-R and, consequently, in defective regeneration of epithelial cells and breakdown of the intestinal barrier. Besides regulating the systemic availability of the proinflammatory cytokine TNF, our results demonstrate that ADAM17 is needed for vital regenerative activities during the immune response. Thus, our mouse model will help investigate ADAM17 as a potential drug target.
UR - http://www.scopus.com/inward/record.url?scp=77955348535&partnerID=8YFLogxK
U2 - 10.1084/jem.20092366
DO - 10.1084/jem.20092366
M3 - Journal articles
C2 - 20603312
AN - SCOPUS:77955348535
SN - 0022-1007
VL - 207
SP - 1617
EP - 1624
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 8
ER -